Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. Antoniotti C, et al. Among authors: ugolini c. Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27. Lancet Oncol. 2022. PMID: 35636444 Clinical Trial.
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.
Fornaro L, Vivaldi C, Parnofiello A, Ugolini C, Aprile G, De Maglio G, Pecora I, Iacono D, Crivelli F, Catanese S, Cardellino GG, Lencioni M, Vasile E, Salani F, Clerico M, Calvetti L, Falcone A, Fasola G, Fontanini G, Montagnani F. Fornaro L, et al. Among authors: ugolini c. Br J Cancer. 2019 Mar;120(5):522-526. doi: 10.1038/s41416-019-0399-4. Epub 2019 Feb 12. Br J Cancer. 2019. PMID: 30745584 Free PMC article.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: ugolini c. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation.
Giannini R, Zucchelli G, Giordano M, Ugolini C, Moretto R, Ambryszewska K, Leonardi M, Sensi E, Morano F, Pietrantonio F, Cremolini C, Falcone A, Fontanini G. Giannini R, et al. Among authors: ugolini c. J Mol Diagn. 2020 May;22(5):685-698. doi: 10.1016/j.jmoldx.2020.02.008. Epub 2020 Mar 13. J Mol Diagn. 2020. PMID: 32173570 Free article.
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
Borelli B, Fontana E, Giordano M, Antoniotti C, Lonardi S, Bergamo F, Pietrantonio F, Morano F, Tamburini E, Boccaccino A, Santini D, Zucchelli G, Pella N, Maiello E, Passardi A, Zaniboni A, Ugolini C, Fontanini G, Falcone A, Nyamundanda G, Sadanandam A, Cremolini C. Borelli B, et al. Among authors: ugolini c. ESMO Open. 2021 Apr;6(2):100073. doi: 10.1016/j.esmoop.2021.100073. Epub 2021 Mar 3. ESMO Open. 2021. PMID: 33676295 Free PMC article.
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Moretto R, Giordano M, Poma AM, Passardi A, Boccaccino A, Pietrantonio F, Tomasello G, Aprile G, Lonardi S, Conca V, Granetto C, Frassoldati A, Clavarezza M, Bertolini AS, Germani MM, Ugolini C, Fontanini G, Masi G, Falcone A, Cremolini C. Moretto R, et al. Among authors: ugolini c. Eur J Cancer. 2021 Aug;153:16-26. doi: 10.1016/j.ejca.2021.04.039. Epub 2021 Jun 12. Eur J Cancer. 2021. PMID: 34126333
In Reply.
Salani F, Ugolini C, Catanese S, Cacciato Insilla A, Fornaro L, Campani D, Vasile E, Fontanini G, Masi G, Vivaldi C. Salani F, et al. Among authors: ugolini c. Oncologist. 2021 Oct;26(10):e1895-e1896. doi: 10.1002/onco.13886. Epub 2021 Jul 17. Oncologist. 2021. PMID: 34176190 Free PMC article.
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C, Korn WM, Marmorino F, Rossini D, Lonardi S, Masi G, Randon G, Conca V, Boccaccino A, Tomasello G, Passardi A, Swensen J, Ugolini C, Oberley M, Tamburini E, Casagrande M, Domenyuk V, Fontanini G, Giordano M, Abraham J, Spetzler D, Falcone A, Lenz HJ, Cremolini C. Antoniotti C, et al. Among authors: ugolini c. Eur J Cancer. 2021 Sep;155:73-84. doi: 10.1016/j.ejca.2021.06.037. Epub 2021 Aug 5. Eur J Cancer. 2021. PMID: 34365081
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features.
Germani MM, Borelli B, Boraschi P, Antoniotti C, Ugolini C, Urbani L, Morelli L, Fontanini G, Masi G, Cremolini C, Moretto R. Germani MM, et al. Among authors: ugolini c. Cancer Treat Rev. 2022 May;106:102382. doi: 10.1016/j.ctrv.2022.102382. Epub 2022 Mar 21. Cancer Treat Rev. 2022. PMID: 35334281 Review.
160 results